Syk inhibitors with high potency in presence of blood.
Thoma, G., Blanz, J., Buhlmayer, P., Druckes, P., Kittelmann, M., Smith, A.B., van Eis, M., Vangrevelinghe, E., Zerwes, H.G., Che, J.J., He, X., Jin, Y., Lee, C.C., Michellys, P.Y., Uno, T., Liu, H.(2014) Bioorg Med Chem Lett 24: 2278-2282
- PubMed: 24726806 
- DOI: https://doi.org/10.1016/j.bmcl.2014.03.075
- Primary Citation of Related Structures:  
4PX6 - PubMed Abstract: 
We describe two series of Syk inhibitors which potently abrogate Syk kinase function in enzymatic assays, cellular assays and in primary cells in the presence of blood. Introduction of a 7-aminoindole substituent led to derivatives with good kinase selectivity and little or no hERG channel inhibition (3b, 10c).
Organizational Affiliation: 
Novartis Institutes for Biomedical Research, Forum 1 Novartis Campus, 4056 Basel, Switzerland. Electronic address: gebhard.thoma@novartis.com.